APA (7th ed.) Citation

Watson, Z. L., Yamamoto, T. M., McMellen, A., Kim, H., Hughes, C. J., Wheeler, L. J., . . . Bitler, B. G. (2019). Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma. Clinical Epigenetics, 11(1), N.PAG. https://doi.org/10.1186/s13148-019-0758-2

Chicago Style (17th ed.) Citation

Watson, Zachary L., Tomomi M. Yamamoto, Alexandra McMellen, Hyunmin Kim, Connor J. Hughes, Lindsay J. Wheeler, Miriam D. Post, Kian Behbakht, and Benjamin G. Bitler. "Histone Methyltransferases EHMT1 and EHMT2 (GLP/G9A) Maintain PARP Inhibitor Resistance in High-grade Serous Ovarian Carcinoma." Clinical Epigenetics 11, no. 1 (2019): N.PAG. https://doi.org/10.1186/s13148-019-0758-2.

MLA (9th ed.) Citation

Watson, Zachary L., et al. "Histone Methyltransferases EHMT1 and EHMT2 (GLP/G9A) Maintain PARP Inhibitor Resistance in High-grade Serous Ovarian Carcinoma." Clinical Epigenetics, vol. 11, no. 1, 2019, p. N.PAG, https://doi.org/10.1186/s13148-019-0758-2.